Save time and jump to the most important pieces.
4 - Imunon, Inc. (0000749647) (Issuer)
4 - Imunon, Inc. (0000749647) (Issuer)
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events Company plans to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025 LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investig
Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provided an update on its clinical development of IMNN-001 including progress toward commencing a Phase 3 study in advanced ovarian cancer, and an update on IMNN-101, its seasonal COVID-19 booster candidate. "The third quarter was a period of important milestones and outstanding progress for IMUNON, driven largely by presentation of highly compelling topline results from our OV
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pat
4/A - Imunon, Inc. (0000749647) (Issuer)
4 - Imunon, Inc. (0000749647) (Issuer)
4 - Imunon, Inc. (0000749647) (Issuer)
8-K - Imunon, Inc. (0000749647) (Filer)
10-Q - Imunon, Inc. (0000749647) (Filer)
8-K - Imunon, Inc. (0000749647) (Filer)
LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pat
LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technolo
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient population compared with the standard-of-care control armOS was extended by 15.7 months in patients receiving three or more doses of IMNN-001 in the 17-dose protocol Patients also receiving maintenance PARP inhibitor therapy demonstrated an OS hazard ratio of 0.41 in the IMNN-001 trial arm with median OS not yet reached at the time of data lockRobust and durable benefit of IMNN-001 observed in OS supported by a three-month improvement in the primary endpoint of progression-free survival (PFS)IMU
Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment
DNA vaccine proof-of-concept study expected to demonstrate an "mRNA better" platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform's potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON's proprietary PlaCCine® platform is being conducted in healthy volunteers as a seasonal COVID-19 vaccine.
This registration statement contains: a base prospectus which covers the offering, issuance and sale by us of up to $75,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, rights and/or units from time to time in one or more offerings; and an "at the market offering" sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $5,500,000 of our common stock that may be issued and sold from time to time under an At the Market Offering Agreement, as amended by Amendment No. 1 to At the Market Offering Agreement, which, as amended, we refer to as the ATM Agreement, with H.C. Wainwright & Co., LLC, or W
Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud
Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company's scientific advisory board. Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He joins current scientific advisory board members Dan H. Bar
SC 13G - Imunon, Inc. (0000749647) (Subject)
SC 13G/A - Imunon, Inc. (0000749647) (Subject)
SC 13G - Imunon, Inc. (0000749647) (Subject)